Cargando…

A practical synthesis of a novel DPAGT1 inhibitor, aminouridyl phenoxypiperidinbenzyl butanamide (APPB) for in vivo studies

Immunotherapy that targets N-linked glycans has not yet been developed due in large part to the lack of specificity of N-linked glycans between normal and malignant cells. N-Glycan chains are synthesized by the sequential action of glycosyl transferases in the Golgi apparatus. It is an overwhelming...

Descripción completa

Detalles Bibliográficos
Autores principales: Mitachi, Katsuhiko, Kurosu, Shou M., Gillman, Cody D., Yun, Hyun Gi, Clemons, William M., Kurosu, Michio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6812346/
https://www.ncbi.nlm.nih.gov/pubmed/31667130
http://dx.doi.org/10.1016/j.mex.2019.09.031
_version_ 1783462642999885824
author Mitachi, Katsuhiko
Kurosu, Shou M.
Gillman, Cody D.
Yun, Hyun Gi
Clemons, William M.
Kurosu, Michio
author_facet Mitachi, Katsuhiko
Kurosu, Shou M.
Gillman, Cody D.
Yun, Hyun Gi
Clemons, William M.
Kurosu, Michio
author_sort Mitachi, Katsuhiko
collection PubMed
description Immunotherapy that targets N-linked glycans has not yet been developed due in large part to the lack of specificity of N-linked glycans between normal and malignant cells. N-Glycan chains are synthesized by the sequential action of glycosyl transferases in the Golgi apparatus. It is an overwhelming task to discover drug-like inhibitors of glycosyl transferases that block the synthesis of specific branching processes in cancer cells, killing tumor cells selectively. It has long been known that N-glycan biosynthesis can be inhibited by disruption of the first committed enzyme, dolichyl-phosphate N-acetylglucosaminephosphotransferase 1 (DPAGT1). Selective DPAGT1 inhibitors have the promising therapeutic potential for certain solid cancers that require increased branching of N-linked glycans in their growth progressions. Recently, we discovered that an anti-Clostridium difficile molecule, aminouridyl phenoxypiperidinbenzyl butanamide (APPB) showed DPAGT1 inhibitory activity with the IC(50) value of 0.25 μM. It was confirmed that APPB inhibits N-glycosylation of β-catenin at 2.5 nM concentration. A sharp difference between APPB and tunicamycin was that the hemolytic activity of APPB is significantly attenuated (IC(50) > 200 μM RBC). Water solubility of APPB is >350-times greater than that of tunicamycin (78.8 mg/mL for APPB, <0.2 mg/mL for tunicamycin). A novel DPAGT1 inhibitor, APPB selectively inhibits growth of the solid tumors (e.g. KB, LoVo, SK-OV-3, MDA-MB-432S, HCT116, Panc-1, and AsPC-1) at low μM concentrations, but does not inhibit growth of a leukemia cell (L1210) and the healthy cells (Vero and HPNE) at these concentrations. In vitro metabolic stability using rat liver microsomes indicated that a half-life (t(1/2)) of APPB is sufficiently long (>60 min) for in vivo studies (PK/PD, safety profiles, and in vivo efficacy) using animal models. We have refined all steps in the previously reported synthesis for APPB for larger-scale. This article summarizes protocols of gram-scale synthesis of APPB and its physicochemical data, and a convenient DPAGT1 assay. • Remember that the abstract is what readers see first in electronic abstracting & indexing services. • This is the advertisement of your article. Make it interesting, and easy to be understood. • Be accurate and specific, keep it as brief as possible.
format Online
Article
Text
id pubmed-6812346
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-68123462019-10-30 A practical synthesis of a novel DPAGT1 inhibitor, aminouridyl phenoxypiperidinbenzyl butanamide (APPB) for in vivo studies Mitachi, Katsuhiko Kurosu, Shou M. Gillman, Cody D. Yun, Hyun Gi Clemons, William M. Kurosu, Michio MethodsX Chemistry Immunotherapy that targets N-linked glycans has not yet been developed due in large part to the lack of specificity of N-linked glycans between normal and malignant cells. N-Glycan chains are synthesized by the sequential action of glycosyl transferases in the Golgi apparatus. It is an overwhelming task to discover drug-like inhibitors of glycosyl transferases that block the synthesis of specific branching processes in cancer cells, killing tumor cells selectively. It has long been known that N-glycan biosynthesis can be inhibited by disruption of the first committed enzyme, dolichyl-phosphate N-acetylglucosaminephosphotransferase 1 (DPAGT1). Selective DPAGT1 inhibitors have the promising therapeutic potential for certain solid cancers that require increased branching of N-linked glycans in their growth progressions. Recently, we discovered that an anti-Clostridium difficile molecule, aminouridyl phenoxypiperidinbenzyl butanamide (APPB) showed DPAGT1 inhibitory activity with the IC(50) value of 0.25 μM. It was confirmed that APPB inhibits N-glycosylation of β-catenin at 2.5 nM concentration. A sharp difference between APPB and tunicamycin was that the hemolytic activity of APPB is significantly attenuated (IC(50) > 200 μM RBC). Water solubility of APPB is >350-times greater than that of tunicamycin (78.8 mg/mL for APPB, <0.2 mg/mL for tunicamycin). A novel DPAGT1 inhibitor, APPB selectively inhibits growth of the solid tumors (e.g. KB, LoVo, SK-OV-3, MDA-MB-432S, HCT116, Panc-1, and AsPC-1) at low μM concentrations, but does not inhibit growth of a leukemia cell (L1210) and the healthy cells (Vero and HPNE) at these concentrations. In vitro metabolic stability using rat liver microsomes indicated that a half-life (t(1/2)) of APPB is sufficiently long (>60 min) for in vivo studies (PK/PD, safety profiles, and in vivo efficacy) using animal models. We have refined all steps in the previously reported synthesis for APPB for larger-scale. This article summarizes protocols of gram-scale synthesis of APPB and its physicochemical data, and a convenient DPAGT1 assay. • Remember that the abstract is what readers see first in electronic abstracting & indexing services. • This is the advertisement of your article. Make it interesting, and easy to be understood. • Be accurate and specific, keep it as brief as possible. Elsevier 2019-09-27 /pmc/articles/PMC6812346/ /pubmed/31667130 http://dx.doi.org/10.1016/j.mex.2019.09.031 Text en © 2019 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Chemistry
Mitachi, Katsuhiko
Kurosu, Shou M.
Gillman, Cody D.
Yun, Hyun Gi
Clemons, William M.
Kurosu, Michio
A practical synthesis of a novel DPAGT1 inhibitor, aminouridyl phenoxypiperidinbenzyl butanamide (APPB) for in vivo studies
title A practical synthesis of a novel DPAGT1 inhibitor, aminouridyl phenoxypiperidinbenzyl butanamide (APPB) for in vivo studies
title_full A practical synthesis of a novel DPAGT1 inhibitor, aminouridyl phenoxypiperidinbenzyl butanamide (APPB) for in vivo studies
title_fullStr A practical synthesis of a novel DPAGT1 inhibitor, aminouridyl phenoxypiperidinbenzyl butanamide (APPB) for in vivo studies
title_full_unstemmed A practical synthesis of a novel DPAGT1 inhibitor, aminouridyl phenoxypiperidinbenzyl butanamide (APPB) for in vivo studies
title_short A practical synthesis of a novel DPAGT1 inhibitor, aminouridyl phenoxypiperidinbenzyl butanamide (APPB) for in vivo studies
title_sort practical synthesis of a novel dpagt1 inhibitor, aminouridyl phenoxypiperidinbenzyl butanamide (appb) for in vivo studies
topic Chemistry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6812346/
https://www.ncbi.nlm.nih.gov/pubmed/31667130
http://dx.doi.org/10.1016/j.mex.2019.09.031
work_keys_str_mv AT mitachikatsuhiko apracticalsynthesisofanoveldpagt1inhibitoraminouridylphenoxypiperidinbenzylbutanamideappbforinvivostudies
AT kurosushoum apracticalsynthesisofanoveldpagt1inhibitoraminouridylphenoxypiperidinbenzylbutanamideappbforinvivostudies
AT gillmancodyd apracticalsynthesisofanoveldpagt1inhibitoraminouridylphenoxypiperidinbenzylbutanamideappbforinvivostudies
AT yunhyungi apracticalsynthesisofanoveldpagt1inhibitoraminouridylphenoxypiperidinbenzylbutanamideappbforinvivostudies
AT clemonswilliamm apracticalsynthesisofanoveldpagt1inhibitoraminouridylphenoxypiperidinbenzylbutanamideappbforinvivostudies
AT kurosumichio apracticalsynthesisofanoveldpagt1inhibitoraminouridylphenoxypiperidinbenzylbutanamideappbforinvivostudies
AT mitachikatsuhiko practicalsynthesisofanoveldpagt1inhibitoraminouridylphenoxypiperidinbenzylbutanamideappbforinvivostudies
AT kurosushoum practicalsynthesisofanoveldpagt1inhibitoraminouridylphenoxypiperidinbenzylbutanamideappbforinvivostudies
AT gillmancodyd practicalsynthesisofanoveldpagt1inhibitoraminouridylphenoxypiperidinbenzylbutanamideappbforinvivostudies
AT yunhyungi practicalsynthesisofanoveldpagt1inhibitoraminouridylphenoxypiperidinbenzylbutanamideappbforinvivostudies
AT clemonswilliamm practicalsynthesisofanoveldpagt1inhibitoraminouridylphenoxypiperidinbenzylbutanamideappbforinvivostudies
AT kurosumichio practicalsynthesisofanoveldpagt1inhibitoraminouridylphenoxypiperidinbenzylbutanamideappbforinvivostudies